Cystatin B Involvement in Synapse Physiology of Rodent Brains and Human Cerebral Organoids

Eduardo Penna, Angela Cerciello, Angela Chambery, Rosita Russo, Filippo M. Cernilogar, Emilia Maria Pedone, Carla Perrone-Capano, Silvia Cappello, Rossella Di Giaimo and Marianna Crispino

Cystatin B (CSTB) is a ubiquitous protein belonging to a superfamily of protease inhibitors. CSTB may play a critical role in brain physiology because its mutations cause progressive myoclonic epilepsy-1A (EPM1A), the most common form of progressive myoclonic epilepsy. However, the molecular mechanisms underlying the role of CSTB in the central nervous system (CNS) are largely unknown. To investigate the possible involvement of CSTB in the synaptic plasticity, we analyzed its expression in synaptosomes as a model system in studying the physiology of the synaptic regions of the CNS. We found that CSTB is not only present in the synaptosomes isolated from rat and mouse brain cortex, but also secreted into the medium in a depolarization-controlled manner. In addition, using biorthogonal noncanonical amino acid tagging (BONCAT) procedure, we demonstrated, for the first time, that CSTB is locally synthesized in the synaptosomes. The synaptic localization of CSTB was confirmed in a human 3D model of cortical development, namely cerebral organoids. Altogether, these results suggest that CSTB may play a role in the brain plasticity and open a new perspective in studying the involvement of CSTB deregulation in neurodegenerative and neuropsychiatric diseases.

Keywords: CSTB, synaptosomes, EPM1A, cerebral organoids, synaptic plasticity, local protein synthesis

INTRODUCTION

Cystatin B (CSTB) is an inhibitor of the cathepsin family of proteases, widely expressed in most cell types and tissues. In the central nervous system (CNS), CSTB has been detected in the dentate gyrus of the hippocampus and in the cerebellum. In particular, the cell type-specific expression of CSTB in developing cerebellum suggests that the expression of this protein is finely regulated (Riccio et al., 2005).
CSTB forms a complex with a number of proteins, some of which are specific to the CNS and exhibit a cytoskeletal localization such as neurofilament protein light chain (NF-L) and brain β-spectrin, suggesting that CSTB may have additional unknown role (Di Giaino et al., 2002; Riccio et al., 2005). It has been proposed that CSTB is involved in the mechanisms preventing cerebral apoptosis (Pennacchio et al., 1998) and protecting neurons from oxidative stress. Consistent with this hypothesis, CSTB knock-out (KO) mice display signs of oxidative stress, progressive ataxia, and neuronal death (Lehtinen et al., 2009). Regulation of the redox state seems to be a crucial mechanism in which CSTB is involved. In fact, CSTB has a high capacity to interact with the superoxide dismutase 1 (SOD-1), a protein that has an important function in preventing the accumulation of reactive oxygen species (ROS; Ulbrich et al., 2014).

Mutations of CSTB cause progressive myoclonic epilepsy-1A (EPM1A), the most common form of progressive myoclonic epilepsy. EPM1A is an autosomal recessive disease, and the genotype of the patients most commonly attain an unstable dodecamer expansion repeat in the promoter region of the CSTB gene, which decreases the gene transcription. Interestingly, the severity of the disease is known to be inversely correlated with the amount of residual functional CSTB protein (Joensuu et al., 2008; O’Brien et al., 2017). Neuronal loss is a feature of CSTB-KO mice with GABAergic signaling pathway particularly affected (Joensuu et al., 2014). Accordingly, a significant reduction in VGAT labeling was observed both in the cortex of CSTB-KO mice and in one EPM1 patient, suggesting a critical role of altered GABA signaling in the development of the disease (Buzzi et al., 2012). Moreover, in the developing cerebellum of pre-symptomatic CSTB-KO mice expressions of several genes related to synaptic development and functions were altered, suggesting that CSTB may be implicated in synaptic plasticity (Joensuu et al., 2014).

CSTB was detected in the senile plaque of Alzheimer’s and Parkinson’s disease, suggesting its role in neurodegenerative diseases (Ii et al., 1993; Žerovnik, 2016). One of the common denominators in many neurodegenerative disorders is the deregulation of synaptic plasticity (Skaper et al., 2018). Indeed, the CNS responds to the injuries with rearrangement of the synaptic contacts, thus the mechanisms underlying synaptic plasticity may be important in understanding the etiopathology of neurodegenerative disease.

The cytoarchitecture of neuronal circuits is maintained “plastic” not only during embryonic development but also throughout adulthood. The ability of neurons to change themselves in response to the stimuli is accountable for the storage of new information into the brain, and for the ability of the organisms to adapt to the changing environment (Wefelmeyer et al., 2016). Neuronal plasticity is expressed not only as the physical rearrangements of subcellular compartments such as dendrites, axon and nerve endings but also by the modulation of the number and strength of synaptic connections. The synaptic plasticity requires rapid but subtle modulation of the proteome especially at the synaptic level, and, in this regard, local protein synthesis plays a key role in remodeling the synaptic regions in response to the external stimuli (Cagnetta et al., 2018).

To date, a great deal of experimental data has demonstrated the importance of the local system of protein synthesis in the physiology of CNS not only during growth cone elongation and axonal outgrowth in the developing brain (Jung et al., 2014), but also for axonal maintenance in mature neurons (Shigeoka et al., 2016). In the CNS of adult rodents, presynaptic protein synthesis is modulated by learning (Eyman et al., 2007) and is known to be required for long term plasticity (Younts et al., 2016).

In this context, it is conceivable that CSTB makes an important contribution to synaptic plasticity. In this article, we demonstrated in adult rat brains the presence of CSTB in the synaptic region. We also showed that CSTB is secreted from synaptosomes in depolarizing conditions and locally synthesized in the synaptosomes. The synaptic localization of CSTB was confirmed also in mouse adult brain and interestingly, in a human 3D model of cortical development, namely cerebral organoids. The synaptic role of CSTB opens a new perspective in understanding the involvement of this protein in the plasticity of the brain and consequently in EPM1 etiology.

**MATERIALS AND METHODS**

**Animals**

Male Wistar rats and C57BL/6 mice (Charles River, Calco, Lecco, Italy) of about 3 months of age were kept in animal house in a temperature-controlled room under a 12-h light-dark regimen (lights on at 6 AM) with food and water *ad libitum*. The animals were anesthetized by intra-peritoneal injection of chloral hydrate (40 mg/100 g body weight) and decapitated with a guillotine. The brain was removed, and brain cortex and cerebellum were quickly dissected and used immediately for synaptosomal preparation.

**Preparation of Synaptosomal Fraction**

Synaptosomal fractions were prepared as previously described (Eyman et al., 2007). Briefly, cerebral cortex (Cx), and cerebellum (Cb) were homogenized in nine volumes of cold isotonic medium (HM: 0.32 M sucrose, 10 mM Tris-HCl, pH 7.4), using a Dounce homogenizer. After centrifugation of the homogenate (2,200 g, 1 min, 4°C), the sediment was resuspended in the same volume of HM and centrifuged under the same conditions to yield a washed sediment containing nuclei, cell debris, and other particulates (P1 fraction). The two supernatant fractions were mixed and centrifuged at a higher speed (22,000 g, 4 min, 4°C), to obtain a second sediment that was resuspended in the same volume of HM and centrifuged as described above. The washed sediment contained free mitochondria, synaptosomes, myelin, and microsomal fragments (P2 fraction). An aliquot of the P2 fraction (1 ml), with a protein concentration of 3.5 mg/ml was layered over a discontinuous gradient of 5% and 13% Ficoll dissolved in HM (2 ml each) and centrifuged at 45,000 g, 45 min, 4°C. The purified synaptosomes were recovered at the interface between the two Ficoll layers, diluted with nine volumes HM and sedimented by centrifugation at 22,000 g, 20 min, 4°C. The sediment was homogenized in HM and used for subsequent analyses.
Gel Electrophoresis and Western Blot Analysis

Aliquots of homogenate and synaptosomes were lysed in RIPA buffer (50 mM Tris-HCl pH 8.8, 150 mM NaCl, 0.1% SDS, 0.5% NP-40, 0.5% DOC; protease and phosphatase inhibitor cocktail, Sigma-Aldrich) and centrifuged in Eppendorf 5415C microcentrifuge at 14,000 rpm, 5 min, 4°C. Proteins (5 µg/lane, in Sample Buffer: 60 mM Tris-HCl pH 6.8, 10% Glycerol, 2% SDS, 100 mM DTT 0.1% bromophenol blue) were separated in 10%–15% SDS-polyacrylamide gel and transferred to PVDF membranes (Merck-Millipore). Western blot analysis was performed as previously reported (Chun et al., 2004; Volpicelli et al., 2019). Briefly, filters were blocked for 2 h at RT in 5% (w/v) non-fat milk in Tris-buffered saline Tween-20 (TBST; 0.1% Tween, 150 mM NaCl, 10 mM Tris-HCl, pH 7.5) and probed with the following antibodies: anti-CSTB (1:4,000, ABIN271833 Antibodies), anti-Synaptophysin (SYP; 1:400,000, AB9272, Merck-Millipore), anti-β-actin (1:2,000, 612656, BD Biosciences), and anti-SOD-1 (1:1,000, ADI-SOD-100, Enzo Life Sciences). After several washings in TBST, membranes were incubated with secondary antibody against rabbit (1:20,000, A0545, Sigma-Aldrich) or mouse (1:20,000, NA931, GE Healthcare) and transferred to the beads and mixed gently on Roto-Torque for 30 min. The samples were exposed to DynaMags for few minutes to separate newly synthetized proteins, bound to Dynabeads, from the rest of the reaction mixture. After four washing using PBS pH 7.4, Dynabeads were boiled in 0.1% SDS for 5 min at 95°C and the newly-synthetized proteins were collected in sample buffer for western blot analysis.

Secretion of Proteins From Synaptosomes

Synaptosomes were incubated in Ringer medium or in depolarizing medium (43 mM NaCl, 50 mM KCl, 2 mM MgCl₂, 1 mM CaCl₂, 1 mM glucose, 100 mM sucrose, 30 mM Tris-HCl, pH 7.5) to detect depolarization-induced secretion. The reaction was initiated by adding the synaptosomal fraction (300 µg/ml) to the incubation medium. Immediately after that, an aliquot of the incubation medium was transferred to ice to stop the reaction (sample at time 0). After 2 h incubation at 37°C, the reaction was stopped by cooling the sample on ice. Synaptosomes were collected by centrifugation at 190,000 g, 20 min, 4°C. Secreted proteins, present in the supernatant, were concentrated by Amicon Centrifugal Filter Devices with a cut-off of 10 kDa (Merck-Millipore) and the concentration was determined by Bradford assay (BIORAD). The synaptosomal proteins, retained in the pellet, were resuspended in RIPA Buffer. Aliquots of all samples in the sample buffer were separated in SDS-PAGE as previously described and visualized by Coomassie gel staining or Western blot; for Coomassie staining gel was placed in Coomassie solution (10% Acetic acid, 25% Isopropyl alcohol, 0.25% Coomassie brilliant blue R-250 SIGMA).

Mass Spectrometry

Tryptic Digestion and Sample Preparation for MS/MS Analyses

All chemicals, tosyl phenylalanyl chloromethyl ketone (TPCK)-treated trypsin were from Sigma Chemical Company (Milan, Italy) unless otherwise stated. Acetonitrile (ACN; CH₃CN), formic acid (FA) and water LC-MS grade were from Fisher Scientific Italia (Rodano, Milano).

Secretomes from incubation of synaptosomes in both Ringer (sample-R) and depolarizing media (sample-D) were precipitated with trichloroacetic acid (TCA). Briefly, 40 µL of ice-cold 100% TCA was added to 160 µL of samples (~50 µg) and the mixtures were incubated for 30 min in ice. Following centrifugation (15 min, 14,000 rpm, 4°C) supernatants were discarded and the protein pellets were washed once with cold diethyl-ether and then with cold acetone. The protein pellets were then dried at room temperature and reconstituted in 50 µL of 50 mM NH₄HCO₃ pH 8.0 containing 10% ACN.

Samples were then subjected to disulfide reduction with DTT (10 mM (1 h at 55°C) and alkylation with iodoacetamide 20 mM (20 min at room temperature in the dark). Enzymatic hydrolyses were performed on reduced and alkylated samples by adding TPCK-treated trypsin with an enzyme/substrate (E/S) ratio of 1:50 (w/w) in two steps. Mixtures were then incubated at 37°C for 16 h and frozen for subsequent analyses (Russo et al., 2019).

High-Resolution nanoLC-Tandem Mass Spectrometry

Mass spectrometry analyses of tryptic digests (2 µg) were performed on a Q-Exactive Orbitrap mass spectrometer equipped with an EASY-Spray nanoelectrospray ion source (Thermo Fisher Scientific, Bremen, Germany) and coupled to
a Thermo Fisher Scientific Dionex UltiMate 3000RSLC nano system (Thermo Fisher Scientific; Russo et al., 2017). The solvent composition was 0.1% FA in water (solvent A) and 0.1% FA in ACN (solvent B). Peptides were loaded on a trapping PepMap™100 μCartridge Column C18 (300 μm× 0.5 cm, 5 μm, 100 Å) and desalted with solvent A for 3 min with at a flow rate of 0.1 μL/min. After trapping, eluted peptides were separated on an EASY-Spray analytical column (50 cm × 75 μm ID PepMap RSLC C18, 3 μm, 100 Å) and heated to 35°C, at a flow rate of 300 nL/min by using the following gradient: 4% B for 3 min, from 4% to 22% B in 50 min, from 22% to 35% B in 10 min, and from 35% to 90% B in 5 min. A washing (90% B for 5 min) and a re-equilibration (4% B for 15 min) step were always included at the end of the gradient. Eluting peptides were analyzed on the Q-Exact mass spectrometer operating in positive polarity mode with a capillary temperature of 280°C and a potential of 1.9 kV applied to the capillary probe. Full MS survey mass spectra were acquired in centroid mode. Charge state (+57.021464 Da) of cysteine and oxidation of methionine were considered. Carbamidomethylation tolerances were set to 10 ppm and 0.02 Da for precursor and fragment ions, respectively.

**Data Processing**

The acquired raw files were analyzed with Proteome Discoverer 2.1 software (Thermo Fisher Scientific) using the SEQUEST HT search engine (Di Giuseppe et al., 2017).

The HCDMS/MS spectra were searched against the Rattus norvegicus database available in UniprotKB (8,018 reviewed entries, release 2018_01, 31-Jan-2018) assuming trypsin (Full) as digestion enzyme with two allowed number of missed cleavage sites and a minimum peptide length of six residues. The mass tolerances were set to 10 ppm and 0.02 Da for precursor and fragment ions, respectively. Carboxymethylation (+57.021464 Da) of cysteine and oxidation of methionine (+15.995 Da) were set as static modifications. Dynamic modifications were searched as: oxidation of methionine, acetyl (m/z 44), nitration (m/z 74), and phosphorylation (m/z 80) of serine, threonine, and tyrosine residues. False discovery rates (FDRs) for peptide spectral matches (PSMs) were calculated and filtered using the Target Decoy PSM Validator Node in Proteome Discoverer.

The Target Decoy PSM Validator Node specifies the PSM confidences based on dynamic score-based thresholds. It calculates the node-dependent score thresholds needed to determine the FDRs, which are given as input parameters of the node. Target Decoy PSM Validator was run with the following settings: maximum Delta Cn of 0.05, a strict target FDR of 0.01, a relaxed target FDR of 0.05 and validation based on q-value. The Protein FDR Validator Node in Proteome Discoverer was used to classify protein identifications based on q-value. Proteins with a q-value below 0.01 were classified as high confidence identifications and proteins with a q-value of 0.01–0.05 were classified as medium confidence identifications. Only proteins identified with medium or high confidence were retained resulting in an overall FDR of 5%. Only proteins identified with a number of unique peptides greater than one were considered.

**Ontology Annotation**

Proteins identified by Mass Spectrometry were assigned to Gene Ontology (GO) biological process groups (Annotation data set: GO biological process complete release 20190202) using the PANTHER Overrepresentation Test (release 20190308; Mi et al., 2017) with default parameters and in reference to the Rattus norvegicus genes as background.

**Cerebral Organoids**

Induced pluripotent stem cells reprogrammed from human newborn foreskin fibroblasts (CRL-2522, ATCC; O’Neill et al., 2018; Klaus et al., 2019) were used to generate cerebral organoids as previously described (Lancaster et al., 2013; Lancaster and Knoblich, 2014). Organoids were kept in 10 cm dishes on an orbital shaker at 37°C, 5% CO2 and ambient oxygen level with medium changes every 3–4 days. Organoids were analyzed at 35 days, 60 days and 70 days after plating. For synaptosomal fraction purification, a pool of 20–40 organoids was collected by centrifugation (500 x g for 10 min). Organoids were resuspended in HM and homogenized in a Dounce homogenizer with nine volumes of HM. The P2 crude synaptosomal fraction was prepared as described above. Homogenate and P2 fraction, resuspended in the sample buffer, were processed for western blot analysis as previously described. For immunostaining 16 μm sections of organoids were made using a cryotome. Immunostainings were performed as described previously (Cappello et al., 2013). Nuclei were visualized using 0.1 μg/ml 4,6-diamidino-2-phenylindole (DAPI, Sigma Aldrich). SYP antibody (AB9272, Merck-Millipore), doublecortin (DCX) antibody (AB2253, Millipore), and CSTB antibody (ABIN223204, Antibodies) were incubated at the dilution of 1:1,000, 1:1,000 and 1:400 respectively. Immunostained sections were analyzed using Leica laser-scanning microscopes.

**Statistical Analyses**

All the statistical analyses were performed using GraphPad Prism 7 software. Data were expressed as mean ± SEM. Differences among groups were compared by ANOVA or t-test as indicated in the Figure legends. Differences were considered statistically significant at p < 0.05.

**RESULTS**

**Presence of Cystatin B in Synaptosomal Fraction From the Rodent Brains**

We isolated synaptosomal fractions from a homogenate of both cerebral cortex and cerebellum of rats as previously described (Eyman et al., 2007). By western blot analysis, we first assessed...
the distribution of a typical cytoskeletal protein, β-actin, in the homogenate and in synaptosomes. As shown in Figures 1A, B, β-actin was slightly less abundant in the synaptosomal fractions of both brain regions in comparison with its levels in the homogenates. By contrast, SYP, a well-known presynaptic protein, was significantly enriched in the synaptosomes of the brain cortex (Figure 1A) and cerebellum (Figure 1B). The differential distribution of these two proteins confirms that the synaptosomal fraction is a subcellular compartment representing the synaptic region of the neuron. When the distribution of CSTB in the synaptic compartment was examined (Figures 1A, B), it was evident that CSTB was present in rat synaptosomal fractions although it was more abundant in the homogenate, in keeping with its well-known cytosolic localization. The presence of CSTB in the synaptic region was also confirmed in the mouse cerebral cortex where the ratio of CSTB in synaptosomes vs. homogenate was even higher than in the rat (Figure 1C). Altogether, these results clearly indicate the synaptic localization of CSTB, suggesting its involvement in synaptic plasticity.

Cystatin B Is Locally Synthesized in the Synaptosomal Fraction of Rat Brains

In view of the crucial role played by synaptic protein synthesis in brain plasticity, we tested if CSTB was locally synthesized in the synaptosomal fraction. To this end, we performed metabolic labeling of newly synthesized proteins using Click-iT™ L-HPG as a precursor (Best, 2009). Newly synthesized proteins incorporating HPG were isolated from the background proteins by biotinylation and subsequent purification with streptavidin beads. In Western blot analysis, CSTB was identified as one of the newly synthesized (HPG-labeled) proteins in the synaptosomes of rat cerebral cortex (Figure 2). The CSTB band was negligible in the negative control, i.e., the reaction mixture of the synaptosomal fraction incubated without HPG. These data demonstrated, for the first time, that CSTB is, at least in part, synthesized in the synaptic region of the rat cerebral cortex.

Cystatin B Is Secreted by Synaptosomes

To investigate the role of CSTB in synaptic physiology, we tested its possible secretion from synaptosomes. Thus, the synaptosomal fraction was incubated for 2 h in physiological extracellular solution (Ringer medium). At the end of the incubation period, the incubation medium was collected, and its contents were concentrated using Amicon filters with a cut-off size of 10 kDa. As judged by the Coomassie blue staining, only few proteins were found secreted in the medium, with a pattern (Figure 3A, lane 5) that was strikingly different from that of synaptosomal proteins (Figure 3A, lane 2). Among the secreted proteins, we detected CSTB by Western blot analysis, while SYP, a very abundant protein of synaptic vesicles, was completely absent. Likewise, β-actin was not present in the incubation medium (Figure 3B, lane 5).

As a next step, we checked if CSTB expression level was modulated by depolarization. Thus, synaptosomes were incubated for 2 h in a depolarizing medium containing high concentration of K⁺ (50 mM, see “Materials and Methods” section). The CSTB, as well as SYP expression levels in synaptosomes did not change in the two incubation conditions (Figure 3B, lanes 2 and 3, and Figure 3C). Interestingly, in depolarizing condition, the amount of secreted CSTB significantly increased compared with the incubation in physiological extracellular solution (Figure 3B, lanes 5 and 6 respectively, and Figure 3D), indicating that the secretion of this protein is regulated by depolarization. SYP, as well as β-actin were not detectable in the incubation medium in both experimental conditions in any of the biological replicates (Figure 3B, lanes 5 and 6).

Mass Spectrometry of the Secreted Proteins

In order to identify the proteins secreted from synaptosomes and to survey the possible presence of known CSTB partners in the secreted medium, we performed a mass-spectrometry
FIGURE 2 | CSTB is locally synthesized in the synaptosomal fraction from rat cerebral cortex. Local synthesis of CSTB was assessed by metabolic labeling of synaptosomal proteins incubated with Homopropargylglycine (HPG) for 2 h as described in “Materials and Methods” section. The newly synthesized proteins, labeled with HPG (green), were biotinylated and isolated by affinity purification using streptavidin beads (yellow). Western blot analysis (representative image from two biological replicates), using CSTB antibody, was performed on synaptosomal proteins (SYN, lane 1), proteins newly synthesized in synaptosomal fraction (lane 2), and negative control (incubation without HPG, lane 3). While 5 µg of proteins were loaded in lane 1, 50% of the pulldown was loaded in lanes 2 and 3 of the SDS gel for the western blot analysis.

analysis of the secreted proteins after 2 h incubation of the synaptosomes either in Ringer medium (sample-R), or in the depolarizing medium (sample-D) by use of nanoLC-Tandem high resolution MS/MS. Using the filtering criteria indicated in “Materials and Methods” section, we detected 253 proteins in sample R and 160 in sample D, with 125 common proteins (Figure 4A; Supplementary Table S1). Among the proteins present in both samples, we identified some of the known partners of CSTB, such as Spectrin beta chain, Neurofilament light polypeptide (Di Giaimo et al., 2002) and SOD1 (Ulbrich et al., 2014), while we did not find any protease target of CSTB such as cathepsin B. The presence of SOD1 and the absence of cathepsin B in the secreted samples was validated by Western blot analysis (Figure 4B). As to the same set of common proteins, the results of GO analysis showed a strong enrichment for the terms related to the synaptic activity (Figure 4C), providing additional hint toward the involvement of CSTB in neuronal plasticity.

Cystatin B Is Present in the Synaptic Regions of Human Cerebral Organoids

To extend our study to humans, we took advantage of the 3D human multicellular model of brain cortical tissue, namely cerebral organoids (Lancaster et al., 2013; Lancaster and Knoblich, 2014; Camp et al., 2015). We first used immunohistochemical analyses to characterize the organoids. The ventricle like structures in the organoids were detected by immunostaining with beta-catenin (CTNNB) that labels adherent junctions allowing the identification of the apical belt, and with DCX that detects young neurons in the cortical plate-like zone (Figures 5A,B,D). To identify synaptic regions, 70 days old human brain organoids were stained with the presynaptic marker SYP (Figure 5C). As shown in Figures 5D,E,E', the colocalization of DCX and SYP indicates that neurons in brain organoids developed in our laboratory express presynaptic markers to a certain extent, already at 70 days. In addition, we observed the localization of CSTB in some of the SYP positive-synaptic regions (Figures 5F,G). We prepared crude synaptosomal fraction (P2) from 35, 60 and 70 days old human brain organoids (pool of 20–40 organoids for each time point), and we analyzed the distribution of SYP, β-actin and CSTB in synaptosomes and in the corresponding homogenates (Figure 5H). SYP is highly enriched in the crude synaptosomal fraction compared to the homogenate, as expected for a pre-synaptic protein. On the other hand, as expected for a ubiquitous cytoskeletal protein, β-actin was equally distributed in the two fractions throughout the developmental stages of the organoids. These data are comparable to the ones obtained from rodent brains fractionation (Figure 1), indicating that synaptosomal fraction prepared from human brain organoids is a good model to study in vitro the synaptic region in a human model. CSTB has a different subcellular distribution than SYP and β-actin, being more abundant in homogenate than in synaptosomes (Figure 5H). These data indicate that in human brain organoids, as in rodent brains, CSTB is mainly a cytosolic protein, although it is partially localized also in the synaptic region. Interestingly, CSTB is almost undetectable in synaptosomal fraction from 35 days old organoids, while its level increases
in synaptosomes at later stages, suggesting that the CSTB localization in the presynaptic terminals progressively increases with neuronal maturation.

DISCUSSION

In the present study, we demonstrated, for the first time, that CSTB is present in the synaptic region of the neuron. In particular, we found CSTB in the synaptosomal fractions of rat and mouse brain cortices. In addition, the presence of CSTB in the synaptosomes was also confirmed in human cerebral organoids. These data indicated that the synaptic location of CSTB is a conserved feature in different mammalian species, and suggested that this small ubiquitous protein may play an important role in brain physiology and plasticity. This hypothesis receives further support from the finding that CSTB is locally synthesized in the synaptic area. Indeed, pinpointing growing body of evidence has suggested that the synaptic system of protein synthesis serves as a crucial mechanism underlying the neuronal plasticity (Crispino et al., 2014; Younts et al., 2016; Cagnetta et al., 2019). Accordingly, its deregulation may contribute to the onset of several brain pathologies including neurodegenerative diseases (Baleriola and Hengst, 2015; Khalil et al., 2018).

To date, the precise mechanism by which CSTB may modulate synaptic plasticity is largely unknown, but several lines of studies have provided some interesting clues. The gene expression data obtained from the cerebellum of CSTB-deficient EPM1 mouse model, revealed that some of the genes involved in synaptic function and plasticity are deregulated already at the pre-symptomatic stage of the disease (Joensuu et al., 2014). This finding suggests that the presence or absence of CSTB may eventually exert its effect on neuronal plasticity by modulating gene expression. On the other hand, CSTB and its interactors were found in a multiprotein complex that included several proteins associated with neuronal physiology (Di Giacomo et al., 2002). Furthermore, the chaperon protein HSP70, which is affecting the folding state of CSTB (Rispoli et al., 2013), was reported to interact with the presynaptic protein syntaxin (Fei et al., 2007) and thereby participates in synapses remodeling (Karunanithi and Brown, 2015).
In this context, our finding that CSTB is locally synthesized at the synaptic region add another layer of control by which the biological activity of CSTB is exquisitely modulated at the synapse.

Another novel finding we report in the present study is that CSTB is secreted by synaptosomes, and its secretion is enhanced by membrane depolarization. This finding suggests that CSTB secretion at the synapse is plastically regulated by neural activity, opening new scenarios for the role of this protein in the CNS. After secretion, what effect CSTB may exert to modulate synaptic plasticity would be an intriguing subject of future study. In this regard, it is tempting to speculate that CSTB, after secretion, could act as a neuroactive peptide or as a neurotrophic factor.

To identify the proteins secreted together with CSTB, we analyzed the synaptosomal incubation medium by mass spectrometry, and we detected several proteins known as binding partners of CSTB (Di Giaino et al., 2002). Interestingly, although by MS we analyzed the same amount of total proteins for both physiological and depolarizing secretomes, fewer proteins were detected in depolarizing secretome. The two samples were overall similar by a technical point of view, as demonstrated by the comparable response of the base peak chromatograms, in terms of the relative intensity of ion signals. Therefore, we can speculate that the identification of fewer proteins in depolarizing medium by MS analysis could depend on effective less complex secretome. However, other factors affecting the total number of identified proteins, such as the different incubation media, cannot be excluded. By GO term enrichment analysis, the secreted proteins were grouped in numerous pathways, several of which were the ones involved in synaptic homeostasis. These results support our hypothesis that CSTB has a functional role in synaptic plasticity and that its deregulation may be part of the molecular synaptic mechanisms underlying the onset of neurodegenerative/neuropsychiatric diseases. Future experiments will address more in details the mechanism of CSTB.
FIGURE 5 | Presence of CSTB in the synaptic regions of cerebral human organoids. (A–E') Confocal microscopic images of human brain organoids (70 days old) immunostained using antibodies against beta-catenin (CTNNB; red), doublecortin (DCX; white), and SYP (green). The cell nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI; blue). In panels (A–E') the white dashed circle indicates the ventricle-like area. (E') Higher magnification of the boxed area in panel (E). (F,G) Confocal microscopic images of sections of human brain organoids (70 days old) immunostained using antibodies against SYP (green), CSTB (red) and DAPI. The arrowheads in (F,G) indicate the colocalized (or very closely apposed) signals of SYP and CSTB. Scale bars, 30 µm in (A–E), 20 µm in (E'), 10 µm in (F,G). (H) Western blot analysis of homogenate (hom) and crude synaptosomal fraction (P2) prepared from a pool of 20–40 cerebral human organoids 35 days, 60 days and 70 days old. Proteins (20 µg) from each fraction were loaded in the gel and the western blot analysis was performed using antibodies specific for beta-actin, SYP, and CSTB.
secretion and the involvement of CSTB in plastic events of nervous system as for instance learning and memory.

An important finding of this work is the demonstration that CSTB is localized in the synaptic region also in a 3D human model of brain cortex, namely cerebral organoids. In terms of shape, size and complexity the human brain is quite distinct from the brains of other mammals commonly used as experimental model systems. In particular, the cerebral cortex is one of the brain regions that have developed most extensively throughout evolution, reaching the highest level of complexity in humans. Therefore, cerebral organoids provide the opportunity to study in vitro the complex interactions and functions of neuronal circuits, underlying unique features of human brain development and disease (Quadraro et al., 2017). The brain organoids may generate different type of cells with apicobasal polarity. Recently, single-cell RNA-sequencing analyses showed the expression of CSTB transcript in many cell types of human cerebral organoids (Velasco et al., 2019). Cerebral organoids can develop for more than 9 months, undergoing significant maturation, including generation of dendritic spines and the formation of spontaneously active neuronal network. Interestingly, our data in 70 days old cerebral organoids, showing some synaptophysin immunolabeling in young neurons (DCX- positive), indicate the presence of synapses already at this early stage of development in culture. Our results are in line with previous data reporting the presence of functional synapses in neurons from 180 days old organoids (Pasca et al., 2015). The crude synaptosomal fraction (P2), isolated for the first time from human cerebral organoids and characterized by the presence of SYP, is expected to provide invaluable insights into the molecular events taking place in the synaptic region of human brain cortex.

The presence of CSTB in the synaptic regions of human brain organoids, demonstrated by immunohistochemistry and western blot analysis on subcellular fractions, supports the hypothesis that this small protein contributes to neuronal plasticity also in humans.

More interestingly, the possibility to build cerebral organoids from the cells of human patients will facilitate in vitro modeling of neurodevelopmental and neuropsychiatric pathologies (Klaus et al., 2019), and thereby provide a new perspective to investigate the synaptic role of CSTB in the cellular and neural circuit dysfunctions related to neuropathologies.

**REFERENCES**

Balariola, J., and Hengst, U. (2015). Targeting axonal protein synthesis in neuroregeneration and degeneration. *Neurotherapeutics* 12, 57–65. doi: 10.1007/s13311-014-0308-8

Best, M. D. (2009). Click chemistry and bioorthogonal reactions: unprecedented selectivity in the labeling of biological molecules. *Biochemistry* 48, 6571–6584. doi: 10.1021/bi9007726

Buzzi, A., Chikhladze, M., Falcicchia, C., Paradiso, B., Lanza, G., Soukupova, M., et al. (2012). Loss of cortical GABA terminals in Unverricht-Lundborg disease. *Neurobiol. Dis.* 47, 216–224. doi: 10.1016/j.nbd.2012.04.005

Cagnotta, R., Frese, C. K., Shigeoka, T., Krijgsveld, J., and Holt, C. E. (2018). Rapid cue-specific remodeling of the nascent axonal proteome. *Neuron* 99, 29.e4–46.e4. doi: 10.1016/j.neuron.2018.06.004

**DATA AVAILABILITY**

All datasets generated for this study are included in the manuscript and/or the Supplementary Files.

**ETHICS STATEMENT**

This study was carried out in strict accordance with the Institutional Guidelines and complied with the Italian D.L. no. 116 of January 27, 1992 of Ministero della Salute and associated guidelines in the European Communities Council Directive of November 24, 1986 (86/609/ECC). All animal procedures reported herein were approved by the Institutional Animal Care and Use Committee (CSV) of University of Naples Federico II.

**AUTHOR CONTRIBUTIONS**

RDG and MC conceived and designed the experiments, analyzed the data, and wrote the manuscript. EP, ACe, ACh, RR and FC performed the experiments, collected the data, and performed the data analyses. EMP, CP-C and SC contributed to the discussion and to the editing of the manuscript.

**FUNDING**

This work was supported by “Finanziamento Ricerca di Ateneo” from University of Naples Federico II.

**ACKNOWLEDGMENTS**

We thank Dr. Roberta Scognamiglio, Dr. Aurora Bracale, Dr. Fabiana Alfieri, and Dr. Ornella Smith for technical assistance, Dr. Jong Tai Chun (Zoological Station “Anton Dohnr,” Naples, Italy) and Prof. Marialuisa Melli (University of Bologna, Bologna, Italy) for critical revision of the manuscript.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnmol.2019.00195/full#supplementary-material

Penna, R., Penna, M., Buzzi, A., Chikhladze, M., Falcicchia, C., Paradiso, B., Lanza, G., Soukupova, M., et al. (2012). Loss of cortical GABA terminals in Unverricht-Lundborg disease. *Neurobiol. Dis.* 47, 216–224. doi: 10.1016/j.nbd.2012.04.005

Cappello, S., Gray, M. J., Badouel, C., Lange, S., Einsiedler, M., Srour, M., et al. (2013). Mutations in genes encoding the cadherin receptor-ligand pair DCHS1 and FAT4 disrupt cerebral cortical development. *Nat. Genet.* 45, 1300–1308. doi: 10.1038/ng.2765

Chun, J. T., Crispino, M., and Tocco, G. (2004). The dual response of protein kinase Fyn to neural trauma: early induction in neurons and delayed induction
in reactive astrocytes. Exp. Neurol. 185, 109–119. doi: 10.1016/j.expneurol.2003.09.019
Crispino, M., Chun, J. T., Cefalíello, C., Perrone Capano, C., and Giuditta, A. (2014). Local gene expression in nerve endings. Dev. Neurobiol. 74, 279–291. doi: 10.1002/dneu.22109
Di Giusto, R., Rispoli, M., Santi, S., Galeotti, C., Ambrosotti, D. C., and Melli, M. (2002). New insights into the molecular basis of progressive myoclonus epilepsy: a multiprotein complex with cystatin B. Hum. Mol. Genet. 11, 2941–2950. doi: 10.1093/hmg.11.23.2941
Di Giusto, A. M. A., Russo, L., Russo, R., Ragucci, S., Caso, J. V., Iserna, C., et al. (2017). Molecular characterization of myoglobin from Sciurus vulgaris meridionalis: primary structure, kinetics and spectroscopic studies. Biochim. Biophys. Acta Proteins Proteom. 1865, 499–509. doi: 10.1016/j.bbapap.2017.02.012
Eyman, M., Cefalíello, C., Ferrara, E., De Stefano, R., Crispino, M., and Giuditta, A. (2007). Synaptosomal protein synthesis is selectively modulated by learning. Brain Res. 1132, 148–157. doi: 10.1016/j.brainres.2006.11.025
Fei, G., Guo, C., Sun, H. S., and Feng, Z. P. (2007). Chronic hypoxia stress-induced differential modulation of heat-shock protein 70 and presynaptic proteins. J. Neurochem. 100, 50–61. doi: 10.1111/j.1471-4159.2006.04194.x
Li, K., Ito, H., Kominami, E., and Hirano, A. (1993). Abnormal distribution of cathepsin proteinases and endogenous inhibitors (cystatins) in the hippocampus of patients with Alzheimer’s disease. Parkinsonism-dementia complex on Guam, and senile dementia and in the aged. Virchows Arch. A Pathol. Anat. Histopathol. 423, 185–194. doi: 10.1007/bf01614769
Joensuu, T., Lehesjoki, A. E., and Kopra, O. (2008). Molecular background of EPM1-Unverricht-Lundborg disease. Epilepsia 49, 557–563. doi: 10.1111/j.1522-8557.2007.01422.x
Joensuu, T., Tegelberg, S., Reimmaa, E., Segerstråle, M., Hakala, P., Pekkonen, H., et al. (2014). Gene expression alterations in the cerebellum and granule neurons of Cstb−/− mice are associated with early synaptic changes and inflammation. PloS One 9:e89321. doi: 10.1371/journal.pone.0089321
Jung, H., Gkogkas, C. G., Sonenberg, N., and Holt, C. E. (2014). Remote control of gene function by local translation. Cell 157, 26–40. doi: 10.1016/j.cell.2014.03.005
Karunanithi, S., and Brown, I. R. (2015). Heat shock response and homeostatic plasticity. Front. Cell. Neurosci. 9.68. doi: 10.3389/fncel.2015.00068
Khalil, B., Morderer, D., Price, P. L., Liu, F., and Rossoll, W. (2018). mRNP assembly, axonal transport, and local translation in neurodegenerative diseases. Brain Res. 1693, 75–91. doi: 10.1016/j.brainres.2018.02.018
Klaus, J., Kanton, S., Kyrousi, C., Ayo-Martin, A. C., Di Giusto, R., Riesenberg, S., et al. (2017). Progressive ataxia, myoclonic epilepsy and cerebellar ataxia in cystatin B-deficient mice. Nat. Genet. 20, 251–258. doi: 10.1038/nn.3509
Quadrato, G., Nguyen, T., Macosko, E. Z., Sherwood, J. L., Min Yang, S., Berger, D. R., et al. (2017). Cell diversity and network dynamics in photosensitive human brain organoids. Nature 545, 48–53. doi: 10.1038/nature22047
Riccio, M., Santi, S., Dembic, M., Di Giusto, R., Cipollini, E., Costantino-Ceccarini, E., et al. (2005). Cell-specific expression of the epm1 (cystatin B) gene in developing rat cerebellum. Neurobiol. Dis. 20, 104–114. doi: 10.1016/j.nbd.2005.02.012
Rispoli, A., Cipollini, E., Catania, S., Di Giusto, R., Pulce, G., von Houte, S., et al. (2013). Insights into progressive myoclonus epilepsy: HSP70 promotes cystatin B polymerization. Biochim. Biophys. Acta 1834, 2591–2599. doi: 10.1016/j.bbapap.2013.09.011
Russo, R., Rega, C., Caporale, A., Tonon, G., Scaramuzza, S., Sels, F., et al. (2017). Ultra-performance liquid chromatography/multiple reaction monitoring mass spectrometry quantification of trastuzumab in human serum by selective monitoring of a specific peptide marker from the antibody complementarity-determining regions. Rapid Commun. Mass Spectrom. 31, 1184–1192. doi: 10.1002/rcm.7899
Russo, R., Valletta, M., Rega, C., Marasco, R., Muscariello, L., Pedone, P. V., et al. (2019). Reliable identification of lactic acid bacteria by targeted and untargeted high-resolution tandem mass spectrometry. Food Chem. 285, 111–118. doi: 10.1016/j.foodchem.2019.01.127
Shigekoa, T., Jung, H., Jung, J., Turner-Bridger, B., Ohk, J., Lin, J. Q., et al. (2016). Dynamic axonal translation in developing and mature visual circuits. Cell 166, 181–192. doi: 10.1016/j.cell.2016.05.029
Skaper, S. D., Facci, L., Zussio, M., and Giusti, P. (2018). An inflammation-centric view of neurological disease: beyond the neuron. Front. Cell. Neurosci. 12:72. doi: 10.3389/fncel.2018.00072
Ulbrich, L., Cozzolino, M., Marin, E. S., Amori, I., De Jach, A., Carli, M. T., et al. (2014). Cystatin B and SOD1: protein-protein interaction and possible relation to neurodegeneration. Cell Mol. Neurobiol. 34, 205–213. doi: 10.1007/s10521-013-0004-y
Velasco, S., Kedaigle, A. J., Simmons, S. K. N., Nash, A., Rocha, M., Quadrato, G., et al. (2019). Individual brain organoids reproducibly form cell diversity of the human cerebral cortex. Nature 570, 523–527. doi: 10.1038/s41586-019-1289-x
Volpicelli, F., Speranza, L., Pulcranio, S., De Gregorio, R., Crispino, M., De Sanctis, C., et al. (2019). The microRNA-29a modulates serotonin 5-HT7 receptor expression and its effects on hippocampal neuronal morphology. Mol. Neurobiol. 56. doi: 10.1007/s12035-019-01690-x [Epub ahead of print].
Wefelmeyer, W., Puhl, C. J., and Burrome, J. (2016). Homeostatic plasticity of subcellular neuronal structures: from inputs to outputs. Trends Neurosci. 39, 656–667. doi: 10.1016/j.tins.2016.08.004
Younts, T. J., Monday, H. R., Dudok, B., Klein, M. E., Jordan, B. A., Katanova, I., et al. (2016). Presynaptic protein synthesis is required for long-term plasticity of GABA release. Neuron 92, 479–492. doi: 10.1016/j.neuron.2016.09.040
Zerovnik, E. (2016). Putative alternative functions of human stefin B (cystatin B): binding to amyloid-beta, membranes, and copper. J. Mol. Recognit. 30:1. doi: 10.1002/jmr.2562

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Penna, Cerciello, Chambery, Russo, Cermigol, Pedone, Perrone-Capano, Cappello, Di Giusto and Crispino. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.